CohBar, Morphogenesis link up in reverse merger of two cancer biotechs

2023-05-23

疫苗免疫疗法信使RNA临床研究

The cancer-focused Bay Area biotech CohBar is entering into a reverse merger with the privately-held biotech Morphogenesis. On Tuesday, CohBar and Morphogenesis announced the all-stock transaction. The newly combined company will operate under the name TuHURA Biosciences and trade on the Nasdaq. The deal is expected to close in the third quarter. TuHURA, which will be based in Tampa, FL, will focus on advancing three products based on Morphogenesis technologies designed to treat cancer. Two are personalized cancer vaccines, which aim to activate an innate immune response against patient-specific tumor antigens. The company is preparing for a Phase II/III trial in 2024 of its lead cancer vaccine, designed to act as an adjunct to Merck’s Keytruda in advanced Merkel cell carcinoma. It is also looking to advance its other mRNA-based vaccine to treat aggressive diffuse large B-cell lymphoma. Morphogenesis’ other product, called Tumor Microenvironment Modulator, is designed to address resistance of immunotherapies.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构